title: [Influence of antihypertensive and metabolic drugs on fatty acids content of lipids in cardiomyocytes of rats with spontaneous hypertension].
abstract: Changes in fatty acid composition of lipids are an important factor in the development of arterial hypertension. Therefore, this is very important to research the role of fatty acid spectrum of the blood and tissues in the development of hypertension. The search for effective metabolic drugs and antihypertensive drugs which would have the additional ability to influence the fatty acid composition of lipids in cells is also important today. We have found that hypertensive rats demonstrate the essential decrease of the amount of saturated fatty acids (sFA) and high content of unsaturated fatty acids (usFA). Application of amlodipine increases the level of sFA compared with animals without treatment and the level of usFA tends to decrease. A similar pattern is observed when using bisoprolol and combination of amlodipine with bisoprolol, although the combination is characterized by more significant changes in FA composition of lipids in cardiomyocytes. Treatment with metabolic drug elgacin leads to full recovery of saturated and unsaturated fatty acids in the cardiomyocytes. During the treatment with combinations of amlodipine with elgacin and bisoprolol with elgacin the level of both types of AF was not significantly different from the elgacin action in monotherapy. This study demonstrates the modification of the FA composition of lipids in cardiomyocytes of the spontaneously hypertensive rats. The investigated drugs exhibit a normalizing influence on the ratio between sFA and usFA in cardiomyocytes of the hypertensive rats.
authors: A M
authors: AM
authors: Puzyrenko
authors: I S
authors: IS
authors: Chekman
authors: T S
authors: TS
authors: Briuzhina
authors: N O
authors: NO
authors: Horchakova
mesh_terms: D017311:Amlodipine / Q000494:pharmacology*; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology*; D017298:Bisoprolol / Q000494:pharmacology*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005227:Fatty Acids / Q000378:metabolism; D005231:Fatty Acids, Unsaturated / Q000378:metabolism; D005260:Female; D005419:Flavonoids / Q000494:pharmacology*; D006973:Hypertension / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008297:Male; D032383:Myocytes, Cardiac / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D051381:Rats; D011918:Rats, Inbred SHR; D014280:Triglycerides / Q000378:metabolism
chemical_list: D000959:Antihypertensive Agents; D005227:Fatty Acids; D005231:Fatty Acids, Unsaturated; D005419:Flavonoids; D014280:Triglycerides; D017311:Amlodipine; D017298:Bisoprolol